Onconova Therapeutics, Inc. And Trawsfynydd Therapeutics, Inc. Announce All-Stock Business Combination, Under Agreement, Onconova Acquired 100% Of Trawsfynydd's Outstanding Equity Shares With A Combined Fully Diluted Equity Value Of $132M; In Connection, Traws Will Raise $14M In Committed Private Placement Financing